Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Veterinary raw materials >  Tigilanol tiglate

Tigilanol tiglate

Basic information Safety Supplier Related

Tigilanol tiglate Basic information

Product Name:
Tigilanol tiglate
Synonyms:
  • Tigilanol tiglate
  • 2-Butenoic acid, 2-methyl-, (1aR,1bR,1cS,2aR,3S,3aS,6aS,6bR,7R,8R,8aS)-1a,1b,1c,2a,3,3a,4,6a,6b,7,8,8a-dodecahydro-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-8a-[(2S)-2-methyl-1-oxobutoxy]-4-oxo-1H-cyclopropa[5',6']benz[1',2':7,8]azuleno[5,6-b]oxiren-8-yl ester, (2E)-
  • EBC 46
  • EBC46
  • EBC-46
  • (1cS,2aR,3S,3aS,6bR,7R,8R,8aS)-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-8a-((2-methylbutanoyl)oxy)-4-oxo-1a
CAS:
943001-56-7
MF:
C30H42O10
MW:
562.65
Mol File:
943001-56-7.mol
More
Less

Tigilanol tiglate Chemical Properties

Boiling point:
682.1±55.0 °C(Predicted)
Density 
1.35±0.1 g/cm3(Predicted)
form 
Solid
pka
10?+-.0.70(Predicted)
color 
White to off-white
InChI
InChI=1S/C30H42O10/c1-9-13(3)23(33)38-21-16(6)28(36)17-11-15(5)20(32)29(17,37)25(35)27(12-31)22(39-27)18(28)19-26(7,8)30(19,21)40-24(34)14(4)10-2/h9,11,14,16-19,21-22,25,31,35-37H,10,12H2,1-8H3/b13-9+/t14-,16+,17-,18+,19+,21+,22-,25+,27-,28-,29+,30+/m0/s1
InChIKey
YLQZMOUMDYVSQR-FOWZUWBHSA-N
SMILES
C(O[C@H]1[C@@]2(OC(=O)[C@@H](C)CC)C(C)(C)[C@@]2([H])[C@]2([H])[C@]3([H])O[C@]3(CO)[C@@H](O)[C@@]3(O)[C@@]([H])(C=C(C)C3=O)[C@@]2(O)[C@@H]1C)(=O)/C(/C)=C/C
More
Less

Tigilanol tiglate Usage And Synthesis

Description

Tigilanol tiglate is a novel small molecule drug approved in Europe for the intratumoural treatment of non-metastatic, unresectable canine mast cell tumours. In addition, Tigilanol tiglate is also used for the treatment of multiple synchronous mast cell tumours in dogs and skin tumours in horses.

Uses

Tigilanol tiglate is a medication used to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs). 

Definition

ChEBI: Tigilanol tiglate is a diterpenoid natural product isolated from the kernels of the Australian blushwood tree (Fontainea picrosperma). It is approved as a veterinary pharmaceutical for the treatment of non-metastatic and non-resectable canine mast cell tumours. It has a role as an antineoplastic agent, a plant metabolite and a protein kinase C agonist. It is a diterpenoid, a phorbol ester, a diester and an organic heteropentacyclic compound.

Mechanism of action

The active substance in Tigilanol tiglate stimulates the action of enzymes called protein  kinase C which are involved in regulating processes that can help cells grow and survive. By activating  these enzymes blood supply to cells gets interrupted, resulting in the death of the cell. By injecting  Stelfonta into the tumour, cancer cells will be affected, so destroying the tumour, and leaving a wound  at the injection site.

in vivo

Tigilanol tiglate (66.5-533 μM, 50 μL, intratumorally) rapidly ablates melanoma xenograft tumors in a concentration dependent manner in BALB/c Foxn1nu nude mice[1].
Tigilanol tiglate (1 mg/mL, 0.5 mL per cm3 of tumor volume, intratumoral) is highly efficacious for the improvement of mast cell tumors in dogs[2].

Tigilanol tiglateSupplier

Shanghai AECOM Biotechnology Co. , Ltd.
Tel
021-021-20956531 18116226605
Email
sui@neosunpharm.com
TargetMol Chemicals Inc.
Tel
15002134094
Email
marketing@targetmol.cn
TargetMol Chemicals Inc.
Tel
+17819995354
Email
marketing@targetmol.com
TargetMol Chemicals Inc.
Tel
+1-781-999-5354;
Email
support@targetmol.com
Hpets Biotech Company (Chongqing) Co.,ltd
Tel
+8613340353813
Email
info@hanpets.com